v3.22.2.2
Other Financial Information
 9 Months Ended
Oct. 02, 2022
Other Financial Information [Abstract]  
Other Financial Information Other Financial Information
A. Inventories
The following summarizes the components of Inventories:
(MILLIONS)October 2,
2022		December 31, 2021
Finished goods$3,159 $3,641 
Work-in-process4,540 4,424 
Raw materials and supplies1,813 994 
Inventories(a)
$9,513 $9,059 
Noncurrent inventories not included above(b)
$3,327 $939 
(a)The increase from December 31, 2021 primarily reflects higher inventory levels for Paxlovid, partially offset by decreases due to net supply recovery and inventory build, and market demand.
(b)Included in Other noncurrent assets. The increase from December 31, 2021 is primarily due to strategic inventory build related to Paxlovid. There are no recoverability issues for these amounts.
B. Other Current Liabilities
Other current liabilities includes, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $4.5 billion as of October 2, 2022 and $9.7 billion as of December 31, 2021.